For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for MKS Inc. (MKSI) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Low · Gem Score -43 (−100…+100 Quality+Value blend) · Quality -6 · Value -68 · Sentiment 35 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
MKS Inc.
MKSI NASDAQMKS Inc. is a global technology company that provides foundational solutions for semiconductor manufacturing, electronics and packaging, and specialty industrial applications. Its products and systems are used to measure, control, deliver, and monitor critical process parameters, supporting advanced manufacturing environments where precision and reliability are essential. The company also supplies photonics, vacuum, and materials technologies used across semiconductor fabrication, precision industrial processing, life and health sciences, research, and defense-related applications. MKS Inc. operates through three main business segments: Vacuum Solutions, Photonics Solutions, and Materials Solutions, giving it a broad role across process control, laser and optics applications, and surface treatment technologies. Headquartered in Andover, Massachusetts, MKS Inc. serves customers worldwide through a diversified portfolio of instruments, subsystems, systems, and specialty chemical offerings.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics TTM · through Jun 30, 2026
EPS (Diluted): 6.24
Total Equity: $2.99B
Shares: 70,466,667
Total Debt: $2.54B
Cash: $454.00M
EBITDA: $1.02B
Total Debt: $2.54B
Cash: $454.00M
Revenue: $4.35B
Revenue: $4.35B
Revenue: $4.35B
Total Equity: $2.99B
Tax Rate: 9.8%
Equity: $2.99B
Total Debt: $2.54B
Cash: $454.00M
Current Liabilities: $2.42B
Long-Term Debt: $2.54B
Total Debt: $2.54B
Total Equity: $2.99B
Shares: 70,466,667
Shares: 70,466,667
CapEx: -$180.00M
Shares: 70,466,667
Stock Price: $240.19
Net Income: $440.00M
Industry Benchmarks
Income Statement (Annual)
Last updated: Sep 10, 2026 12:10pm (27d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.5B | $3.6B | $3.6B | $3.9B |
| Cost of Revenue | $1.6B | $2.0B | $2.0B | $1.9B | $2.1B |
| Gross Profit | $1.4B | $1.5B | $1.6B | $1.7B | $1.8B |
| Operating Expenses | $681.3M | $930.0M | $3.2B | $1.2B | $1.3B |
| Operating Income | $698.9M | $617.0M | -$1.6B | $498.0M | $528.0M |
| Net Income | $551.4M | $333.0M | -$1.8B | $190.0M | $295.0M |
| EBITDA | $803.0M | $833.0M | -$1.2B | $846.0M | $872.0M |
| EPS | $9.95 | $5.57 | $-27.54 | $2.82 | $4.39 |
| EPS (Diluted) | $9.90 | $5.56 | $-27.54 | $2.81 | $4.37 |
Balance Sheet (Annual)
Last updated: Sep 10, 2026 12:10pm (27d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $507.0M | $420.0M | $418.0M |
| Total Current Assets | $2.1B | $2.8B | $2.7B | $2.5B | $2.5B |
| Total Assets | $4.5B | $11.5B | $9.1B | $8.6B | $8.8B |
| Current Liabilities | $460.8M | $952.0M | $848.0M | $775.0M | $927.0M |
| Long-Term Debt | $825.0M | $5.1B | $5.0B | $4.4B | $4.1B |
| Total Liabilities | $1.7B | $7.0B | $6.6B | $6.3B | $6.1B |
| Total Equity | $2.9B | $4.5B | $2.5B | $2.3B | $2.7B |
| Retained Earnings | $2.0B | $2.3B | $373.0M | $503.0M | $711.0M |
Cash Flow (Annual)
Last updated: Sep 10, 2026 12:10pm (27d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $639.5M | $529.0M | $319.0M | $528.0M | $645.0M |
| Capital Expenditure | -$86.7M | -$164.0M | -$87.0M | -$118.0M | -$148.0M |
| Free Cash Flow | $552.8M | $365.0M | $232.0M | $410.0M | $497.0M |
| Acquisitions (net) | -$268.4M | -$4.5B | $0 | $0 | — |
| Net Debt Issued / (Repaid) | -$15.2M | -$962.0M | -$403.0M | -$2.4B | -$451.0M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | $0 | $0 | -$45.0M |
| Net Change in Cash | $358.0M | -$57.0M | -$34.0M | -$161.0M | -$39.0M |
Growth Trends (YoY %)
Last updated: Sep 10, 2026 12:10pm (27d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +20.3% | +2.1% | -1.0% | +9.6% |
| Gross Profit Growth | +12.1% | +6.1% | +4.0% | +7.6% |
| Operating Income Growth | -11.7% | -351.9% | +132.0% | +6.0% |
| Net Income Growth | -39.6% | -652.9% | +110.3% | +55.3% |
| EBITDA Growth | +3.7% | -238.9% | +173.1% | +3.1% |
Dividend History (Last 20)
Last updated: Sep 17, 2026 4:03pm (20d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-08-25 | $0.25 | — | — | — |
| 2026-06-03 | $0.25 | — | — | — |
| 2026-02-23 | $0.25 | — | — | — |
| 2025-11-24 | $0.22 | — | — | — |
| 2025-08-25 | $0.22 | — | — | — |
| 2025-05-27 | $0.22 | — | — | — |
| 2025-02-24 | $0.22 | — | — | — |
| 2024-11-25 | $0.22 | — | — | — |
| 2024-08-26 | $0.22 | — | — | — |
| 2024-05-24 | $0.22 | — | — | — |
| 2024-02-23 | $0.22 | — | — | — |
| 2023-11-24 | $0.22 | — | — | — |
| 2023-08-25 | $0.22 | — | — | — |
| 2023-05-26 | $0.22 | — | — | — |
| 2023-02-24 | $0.22 | — | — | — |
| 2022-11-25 | $0.22 | — | — | — |
| 2022-08-05 | $0.22 | — | — | — |
| 2022-05-26 | $0.22 | — | — | — |
| 2022-02-25 | $0.22 | — | — | — |
| 2021-11-26 | $0.22 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-17 16:13The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw quarterly trajectory first: revenue has climbed from $896M (Q3'24) to $1.25B (Q2'26), a genuine 39% two-year acceleration, with the most recent quarter showing a step-change to 14% net margin ($175M NI on $1.25B). TTM revenue is roughly $4.35B and TTM net income around $440M, giving forward-looking EPS closer to $6.60 and a P/E around 36x — not the 54x on stale $4.37 TTM EPS the pre-flight cites. That matters: the earnings ramp is real and steep (Q2'26 NI of $175M annualizes to $700M if sustained, implying ~23x forward). The synthesis's $109 fair value assumes normalization back to something like the 2024 run-rate; the Q2'26 print explicitly contradicts that assumption.
That said, I don't buy the bull case at $240 either. Net debt is $3.73B against $2.72B equity — this is a leveraged rollup (Atotech legacy), and the 2023 -$1.84B loss reminds us what happens when the cycle turns and goodwill gets tested. Gross margin at 47% is decent but not fortress-tier; MKS is a subsystem supplier, not a monopolist. Applied and Lam operate at 45-48% op margins; MKS is at 15.7%. The "platform-monopoly" archetype in the narrative layer is overreach — MKS is a critical-but-substitutable component vendor whose pricing power depends on WFE cycle tightness. Insider selling in June 2026 (six sales clustered, ~13K shares total) is consistent with executives ringing the register into strength, not a fraud signal but not a confidence signal either.
Where I disagree with the models: the synthesis's $109 fair value is too punitive given the Q2'26 inflection — if you take $700M normalized earnings and slap a 20x multiple (reasonable for a cyclical with recurring exposure and leverage), you get ~$14B market cap or ~$210/share. If you're more conservative and assume Q2 was a peak-cycle quarter and normalized NI is $500M, 18x gets you $9B or ~$135/share. Fair value band is $135–$210, centered around $170. The market forces "value trap" call is too negative; the pre-flight "cyclical trough" framing is stale (the trough was 2024, we're mid-recovery). The narrative layer's 55/45 story/DCF split is directionally right but under-credits the earnings acceleration.
Contrarian check: what if Q2'26 margin expansion is durable because of Atotech synergies finally landing plus WFE mix shift to advanced packaging (higher-margin process control)? Then $700M+ becomes a floor and $240 is fair. What kills that thesis: China WFE spending rolling over (tariff/export-control driven), memory capex pausing after the current DRAM/HBM build, or a single quarter of margin reversion revealing Q2 was a one-off working-capital or tax benefit (NI jumped from $84M to $175M in one quarter — that's suspiciously large and deserves 10-Q scrutiny before extrapolation). I'd flag that $175M print as needing verification; if half of it is non-recurring, my fair value drops toward $170.
Net: I partially dissent from the "overvalued to $110" synthesis. The stock is modestly rich, not 54% overpriced. At $240 with $3.73B net debt and a suspiciously good Q2, the risk/reward is unfavorable but not disastrous — I'd call it 10-15% overvalued, not 54%. Wait for the next print to confirm the margin step-up before touching it long; if $175M NI proves durable, this is fairly valued in the low $200s and could re-rate higher on continued WFE strength.
GPT Reading
What jumps out is that the raw business is recovering much faster than the valuation models seem to admit, but the stock has already moved far enough that you are no longer being paid for much cyclical risk. On a TTM basis through 2026-06-30, revenue is about $4.35 billion and net income is $440 million, versus roughly $3.74 billion and $266 million in the prior-year TTM window. That is around 16% revenue growth and 65% earnings growth, with quarterly revenue stepping from $988 million to $1.03 billion to $1.08 billion to $1.25 billion. The June quarter especially matters: 26% year-over-year growth and 14% net margin against 6.4% a year earlier. This is not a business stuck at trough earnings. The margin structure is rebuilding, and the TTM operating margin near 15.7% suggests the ugly 2023 impairment/reset period is firmly in the rearview mirror.
The balance sheet is the part that keeps me from getting fully bullish. MKS still carries $4.15 billion of debt against just $418 million of cash and $2.72 billion of equity. Even if free cash flow at the latest annual run rate of $497 million remains healthy, net debt is still roughly $3.7 billion, which is material for a cyclical semiconductor equipment supplier. The current ratio of 1.14 is adequate, not comforting. This leverage was easier to tolerate when the shares traded like a stressed cyclical; at a $15.9 billion market cap and about 17.8x EV/EBITDA, investors are now paying a quality-growth multiple for a company that remains exposed to capex swings. The P/E around 38x also looks rich even if depressed earnings understate mid-cycle power, because we are no longer looking at depressed numbers only: net income has already climbed to $175 million in the latest quarter.
So my read is not that MKS is broken or a “value trap.” It is that the business fundamentals are good and improving, but the stock already reflects a large share of that improvement. The annual history shows why caution matters. In 2021 MKS earned $551 million on $2.95 billion of revenue; in 2022 it earned $333 million on $3.55 billion; in 2023 it lost $1.84 billion. That is an extreme earnings profile for a company the market is presently capitalizing at nearly 3.9x sales and 5.7x book. Yes, 2023 was distorted by large charges, but the point stands: this is not software-like resilience. If I annualize nothing and just respect the TTM, investors are paying about 36x-38x earnings and roughly 32x annual free cash flow. That can work for a secular compounder; for a levered semi-cap equipment and subsystems name, it looks full.
The strongest case against my caution is straightforward: the current quarter may be the start, not the end, of the earnings snapback. Gross margin is about 47%, ROIC has improved sharply to 12.1% TTM, operating cash flow of $645 million and FCF of $497 million show the earnings recovery is translating into cash, and the revenue trajectory is accelerating rather than flattening. If the June quarter’s $175 million of net income is closer to the forward run rate than the TTM average, annualized earnings power could be $700 million or more, which would pull the effective forward P/E into the low 20s. On that framing, today’s price is not crazy at all. I also do not put much weight on the insider selling tape here; the sizes are modest relative to market cap and tell me little without more context on 10b5-1 plans or ownership levels.
What would change my mind is mostly in the next two quarters. If revenue can stay above $1.2 billion and net margin can hold in the 13%-14% range, then TTM net income would re-rate quickly toward $550 million-$650 million and the stock would start to justify $240, especially if debt comes down by a few hundred million dollars. Conversely, if the June quarter proves to be a local peak and revenue falls back toward $1.05 billion-$1.10 billion with margins slipping under 10%, then the market is paying a premium multiple on peakish numbers. At today’s price I think the stock is closer to fairly valued-to-slightly overvalued than deeply mispriced, with fair value more in the $190-$215 range unless the latest quarter becomes the new baseline.
Grok Reading
The numbers tell a genuine cyclical recovery that is still gathering speed, not a finished story. TTM revenue through mid-2026 sits near $4.35B (988 + 1.03B + 1.08B + 1.25B), already well above the $3.93B full-year 2025 print, with the June quarter alone at $1.25B and a 14% net margin—the best sequential step-up in years. Net income has climbed from the mid-teens-of-millions trough zone into a $440M TTM run-rate, and the latest quarter’s $175M alone annualizes north of $700M if sustained. Gross margin holds near 47% and operating margin has expanded to roughly 15.7% TTM; free-cash-flow generation of $497M against only $148M capex in the latest annual period confirms the earnings are converting. That is the opposite of a stalled mature earner: volume and mix are improving as semi and advanced-packaging demand re-accelerates. The 2023 wipeout (–$1.84B NI) looks like a one-time impairment hangover from the Atotech-era balance-sheet reset rather than a recurring earnings quality problem.
Leverage and cash conversion still constrain the bull case. Year-end 2025 debt of $4.15B against $418M cash leaves net debt near $3.7B and a current ratio of only 1.14; ROIC has improved to 12.1% TTM but remains well below the mid-teens-plus levels that would justify a structural re-rating. At $240 the stock trades 38.5× TTM earnings, 3.9× sales and 17.8× EV/EBITDA—multiples that already embed continued mid-teens revenue growth and further margin expansion. Insider activity is unambiguously one-way: repeated open-market sales through mid- and late-2026 with no offsetting purchases. FCF yield on the $15.9B equity value is only ~3%, and EV/FCF sits uncomfortably high once net debt is layered in. The acceleration is real; the price already owns most of it.
The strongest contrary argument is that the composite models’ ~$110 fair-value anchor is too punitive and ignores the operating inflection. A skeptic of the overvaluation call would note that annualizing the June quarter’s run-rate produces EPS well above $10, which would drop the forward multiple into the mid-20s—perfectly ordinary for a semi-adjacent process-control name early in a WFE up-cycle—and that $497M of FCF already covers interest and the modest dividend with room to de-lever. They would also argue the 10% revenue CAGR and 65% earnings rebound demonstrate pricing power and share gains that the DCF’s mature 8–10% WACC and normalized-cycle assumptions simply discard. I weigh those points as real but incomplete: one strong quarter does not re-rate a leveraged cyclical permanently, the balance-sheet cushion is thin, and the narrative premium (AI fab stickiness, platform-monopoly framing) still accounts for roughly half the $240 price. Until net debt falls materially and FCF compounds for several more quarters, the multiple remains a claim on perfection rather than a discount to it.
What flips the verdict is concrete: two more quarters of revenue holding above $1.2B with net margins staying in double digits, a clear reduction in net debt below $3B, or a sustained FCF run-rate above $600M that drives FCF yield back toward 5%. Conversely, any sequential revenue stall below $1.1B, margin compression back under 8%, or further large insider sales into strength would confirm the premium is fragile and push the stock toward the mid-100s.
Qwen Reading local experiment · off-panel
The most glaring contradiction in this dataset is the disconnect between the "Mature Earner" classification and the actual earnings trajectory. The rule-based model labels MKS as a mature earner with 63% confidence, yet the data shows a company in violent recovery mode: net income swung from a $1.84B loss in 2023 to $295M in 2025, and the most recent quarter (June 2026) posted a 14% net margin on $1.25B in revenue, up from 6.4% in the same quarter a year prior. This is not a mature, stable cash cow; it is a cyclical industrial company emerging from a trough with accelerating momentum. The "Valuation Synthesis" verdict of "overvalued" at a fair value of ~$109 is fundamentally flawed because it likely anchors to a normalized, low-growth baseline that ignores the current inflection point. At $240.19, the stock trades at 38.5x TTM P/E, which looks expensive on a trailing basis, but the TTM EPS is depressed by the 2023-2024 trough. If we look at forward earnings power, the 16.3% recent revenue YoY growth and the 65.4% earnings YoY growth suggest the market is pricing in a return to historical operating margins (15-20%) rather than the current 10-14% net margin. The "Market Forces" signal calling this a "value trap" is particularly ironic given the strong FCF quality ($497M FCF in 2025) and the accelerating quarterly revenue trend. The insider selling is a red flag, but the volume is trivial (300 to 10,000 shares) relative to a $15.9B market cap, likely routine tax planning or diversification rather than a signal of impending doom.
The strongest case against my bullish read is the balance sheet and the narrative risk. MKS carries $4.15B in total debt against only $418M in cash, resulting in a debt-to-equity ratio of 0.85. In a high-interest-rate environment, this leverage is a drag on ROIC (12.1% TTM), which is respectable but not exceptional for a tech-adjacent industrial. The "Market Narrative" layer correctly identifies that 55% of the price is "story" rather than DCF. The bull case relies on MKS being an "irreplaceable subsystem provider" in the AI/advanced packaging cycle. If the semiconductor capex cycle normalizes faster than expected, or if competition from Applied Materials or Lam Research erodes MKS's niche in vacuum and photonics, the 38x P/E multiple will compress rapidly. The "Lagging Sector Peers" signal is a critical data point: if MKS is underperforming its direct competitors (AMAT, LRCX) despite similar exposure to the AI capex cycle, it suggests the market is questioning the durability of MKS's specific product mix. The 46% drawdown from 52-week highs indicates that the market has already de-risked significantly, but the current price still assumes a sustained 10%+ revenue CAGR (the 5-year CAGR is 10.2%) with expanding margins. If the "AI capex" narrative cools, the multiple could easily re-rate to 20-25x, implying a 30-40% downside.
What would change my mind is the next two earnings reports, specifically the gross margin trend and the guidance for the next two quarters. If gross margins fail to expand beyond the 47% TTM level, or if management guides for flat revenue growth in the next two quarters, the "accelerating" narrative collapses, and the stock becomes a value trap. Conversely, if the next quarter shows gross margins above 48% and revenue growth above 18%, it confirms the "platform-monopoly" narrative and justifies the premium multiple. I am also watching the debt levels; if MKS uses its strong FCF to pay down debt, the ROIC will improve, supporting the valuation. The insider selling is a minor negative, but the volume is too low to be a decisive factor. The key is whether the "story" of AI-driven capex durability holds up against the "fundamentals" of a leveraged, cyclical industrial company.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
MKS is a mature industrial/scientific instruments earner that has clearly turned the corner from its 2023 trough (-$1.75B net loss, -36.9% op margin, tied to Atotech-related charges) back to healthy operating footing: TTM revenue $4.35B (up from $3.58B two years ago), gross margin steady near 47%, operating margin rebuilding to 15.7%, net income $440M, and FCF $455M. Earnings quality checks are clean — Beneish M -2.32, accruals -6.8% of assets, OCF/NI 14.16x (flattered by prior write-downs but directionally healthy), and no mechanical red flags. The offset is the balance sheet and per-share discipline. Net debt of roughly $2.09B against $454M cash is a real constraint (Altman Z 2.54, grey zone), a legacy of the Atotech deal. Diluted shares have grown from 55.8M in 2022 to 70.5M in 2026 — ~6% CAGR — while buybacks recover only 17.7% of SBC, so per-share value is being quietly diluted even as the business improves. Insider tape is one-sided: 24 sells / 0 buys over 12 months across multiple named officers (Colella, Henry, Donahue, Lee, Schreiner), which is notable though not extreme in dollar terms ($23.5M). Net-net: a competent, cash-generative business rebuilding profitability, but carrying acquisition debt and leaking per-share value, with no insider conviction on the buy side.
Verify before trusting this (6)
- Debt maturity ladder and covenant terms on the Atotech-era debt
- Segment mix and customer concentration in semiconductor vs electronics/specialty
- SBC grant structure and whether recent share growth includes M&A-related issuance
- Whether the OCF/NI ratio normalizes once prior non-cash charges roll off
- Nature of 2023 impairments and any remaining goodwill exposure
- 10b5-1 status of the recent insider sales
The composite fair value of $108.82 (signal-adjusted $109.89) sits 54% below the $240.19 price. Even the most generous method in the stack, the anchored-PE at $223.64, only gets you roughly to today's tape, and the DCF at $96.98 and EPV floor at $17.68 argue the market is capitalizing peak-cycle earnings as a run-rate. Quality is Solid, not exceptional, with $2.09B net debt and ~6% annual share creep - that argues for a modest premium to intrinsic, not a 2.2x multiple of DCF. What's priced in: WFE spend keeps compounding, Atotech synergies land, and margins hold through the next cyclical digestion. That's a heroic stack of assumptions for a cyclical instruments supplier. I don't see catastrophic overpricing - anchored-PE says the earnings power can support something in the low-$200s if the cycle holds - but there is no discount here and the asymmetry is negative if fab capex normalizes.
Verify before trusting this (5)
- Forward WFE guidance from ASML/AMAT/LRCX and any MKSI commentary on fab utilization
- Atotech segment margin trajectory and synergy realization
- Debt paydown pace and refinancing terms on the $2.09B net debt
- Share count trajectory - is the 6% creep decelerating
- Backlog and book-to-bill by segment to test peak-cycle risk
The dominant force on MKSI is the semiconductor-capex / AI-buildout narrative. It is a strong, platform-monopoly story with moderate durability, and adjacent tape confirmation is fresh: KLAC up 40% YTD on the same AI process-control thesis is the exact read-through MKSI trades on. Momentum bears this out - 16.3% recent versus 10.2% long-term, with a +9.9pp three-year acceleration - so the story is being paid for, not doubted. That is a real tailwind for a name whose entire multiple is narrative-supported. Against that, the tape just flipped risk-off (VIX 17.7, S&P -3.2% from highs, 10y at 5%, market PE 24.6). With a 1.97 beta and a valuation that the brief itself flags as pricing perfect execution, MKSI is exactly the profile that gets marked down first in any de-risking episode. The regime is only one day old and shallow, so it is a crosswind, not a dominant force yet, but it neutralizes some of the narrative lift. Net: narrative and sector momentum outweigh a nascent macro headwind, so pressure leans up - but fragile, and any deeper VIX spike or capex-cycle wobble would flip it fast.
Verify before trusting this (4)
- Whether the risk-off regime deepens beyond 1 day (VIX through 20, S&P drawdown widening) - would flip the read to headwind fast
- Any Applied Materials / Lam / ASML capex commentary or China wafer-fab equipment restriction headlines that crack the semi-cap narrative
- Analyst target revisions and estimate direction into the next print - divergence from the KLAC-style upgrade cycle would signal narrative fatigue on MKSI specifically
- Momentum breakdown: loss of the recent uptrend or a peer-group rollover in SOX / semi-cap ETFs
The demand that matters to MKS is AI-driven: leading-edge logic capacity, HBM/DRAM, and above all advanced packaging and substrate build-out, where MKS's chemistry and photonics content per wafer/panel is rising rather than merely tracking unit volumes. That is a genuine content-growth mechanism, not a tide story. Against it sits the oldest fact about semi-cap: it is a capex derivative. Fab spending is currently running ahead of end-device demand, and subsystem suppliers absorb inventory digestion earlier and harder than OEMs. Layer on 5% long rates constraining broader industrial/specialty end-markets and China policy risk, and the honest read is a strong two-to-six-quarter runway sitting on top of a cycle whose normalization timing — not existence — is the open question.
Prediction unavailable. valuation-synthesis has no result for MKSI — the prediction needs its fair-value anchors.